Cell Growth & Differentiation, Vol 2, Issue 5 235-243, Copyright © 1991 by American Association of Cancer Research

ARTICLES

Differential regulation of the p72-74 RAF-1 kinase in 3T3 fibroblasts expressing ras or src oncogenes

JC Reed, S Yum, MP Cuddy, BC Turner and UR Rapp
Department of Pathology, University of Pennsylvania School of Medicine, Philadelphia 19104-6082.

The c-raf-1 protooncogene encodes a p72-74 serine/threonine-specific kinase that has been implicated in growth factor-mediated signal transduction and malignant transformation. Here, we compared the effects of Ha-c-ras and v-src oncogenes on the regulation of p72-74 RAF-1 kinase in NIH3T3 cells. In both serum-starved and platelet-derived growth factor-treated v-src-transformed cells, the RAF-1 kinase was constitutively activated, displaying characteristic retarded mobility in electrophoretic gels and elevated activity in in vitro kinase assays. In contrast, the RAF-1 protein from quiescent ras-transformed cells did not exhibit constitutively shifted gel mobility or elevated kinase activity but did respond normally with regard to platelet-derived growth factor- and phorbol myristate acetate-induced changes in p72-74 RAF-1 phosphorylation and kinase activity. 3T3 cells transformed by ras, however, contained elevated levels of p72-74 RAF-1 protein (as determined by immunoblotting), suggesting an indirect influence on this kinase. Quantitative differences in the levels and subcellular distribution of immunodetectable protein kinase C enzymes did not account for the differences between src- and ras-transformed 3T3 cells with regard to regulation of the RAF kinase. These findings in serum-deprived 3T3 cells demonstrate that expression of a ras oncogene can be insufficient for full activation of the p72-74 RAF-1 kinase, implying necessity for an additional growth factor-mediated stimulus.

This article has been cited by other articles:

				L. M. Fedorov, T. Papadopoulos, O. Y. Tyrsin, T. Twardzik, R. Gotz, and U. R. Rapp Loss of p53 in craf-induced Transgenic Lung Adenoma Leads to Tumor Acceleration and Phenotypic Switch Cancer Res., May 1, 2003; 63(9): 2268 - 2277. [Abstract] [Full Text] [PDF]